Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirusiniai vaistai sisteminiam naudojimui - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantais, pasirinktinio imunosupresantais - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.58% , veiklioji

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolaktonas - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ir 5.